Journal Options Hepatitis
Course Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, LTC, MC
Featured Expert Commentary
Tarek Hassanein, MD
Professor of Clinical Medicine and Surgery
Division of Gastroenterology and Hepatology
University of California, San Diego
Director of Liver Transplantation
UCSD Liver Center
University of California, San Diego
San Diego, California
Recent Articles
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection.
McHutchison JG, Everson GT, Gordon SC, et al. New Engl J Med. 2009;360:1827-1838. Capsule Summary | Expert Commentary | Abstract | Slides
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
Bacon BR, Shiffman ML, Mendes F, et al. Hepatology. 2009;49:1838-1846. Capsule Summary | Expert Commentary | Abstract | Slides
The effect of fatigue on driving skills in patients with hepatic encephalopathy.
Bajaj JS, Hafeezullah M, Zadvornova Y, et al. Am J Gastroenterol. 2009;104:898-905. Capsule Summary | Expert Commentary | Abstract | Slides
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
Di Bisceglie AM, Shiffman ML, Everson GT, et al. N Engl J Med. 2008;359:2429-2441. Capsule Summary | Expert Commentary | Abstract | Slides
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
Lok AS, Seeff LB, Morgan TR, et al. Gastroenterology. 2009;136:138-148. Capsule Summary | Expert Commentary | Abstract | Slides
Rifaximin for treatment of hepatic encephalopathy.
Maclayton DO, Eaton-Maxwell A. Ann Pharmacother. 2009;43:77-84. Capsule Summary | Expert Commentary | Abstract | Slides
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P, Heathcote EJ, Buti M, et al. N Engl J Med. 2008;359:2442-2455. Capsule Summary | Expert Commentary | Abstract | Slides
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
Moucari R, Mackiewicz V, Lada O, et al. Hepatology. 2009;49:1151-1157. Capsule Summary | Expert Commentary | Abstract | Slides
Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Gastroenterology. 2009;136:856-862. Capsule Summary | Expert Commentary | Abstract | Slides
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alfa-2b.
Buster EH, Flink HJ, Cakaloglu Y, et al. Gastroenterology. 2008;135:459-467. Capsule Summary | Expert Commentary | Abstract | Slides
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Volume 3, Issue 2
Collection
Hepatitis Journal Options – Volume 3, Issue 2
Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, LTC, MC
  
- Jasmohan Bajaj, MD, MSc
- Wissam Bleibel, MD
- Steven Flamm, MD
|
  
- Ira M. Jacobson, MD
- Daryl T-Y Lau, MD, MSc, MPH
- Kevin Mullen, MD
|
  
- David R. Nelson, MD
- Nancy Reau, MD
- Richard K. Sterling, MD, MSc, FACP, FACG
|
 |
Volume 3, Issue 1
Collection
Journal Options Hepatitis - Volume 3, Issue 1
Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, LTC, MC
 
- Hari S. Conjeevaram, MD, MSc
- Adrian M. Di Bisceglie, MD, FACP
- Tarek Hassanein, MD
|
  
- Donald M. Jensen, MD
- Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
- Robert P. Perrillo, MD
|
- K. Rajender Reddy, MD
- Mark S. Sulkowski, MD
|
|